Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to -$128000.0.

  • Angiodynamics' Other Non Operating Income fell 116666.67% to -$128000.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $4.8 million, marking a year-over-year increase of 82933.13%. This contributed to the annual value of $4.9 million for FY2025, which is 70514.08% up from last year.
  • As of Q4 2025, Angiodynamics' Other Non Operating Income stood at -$128000.0, which was down 116666.67% from -$178000.0 recorded in Q3 2025.
  • Angiodynamics' Other Non Operating Income's 5-year high stood at $5.4 million during Q1 2025, with a 5-year trough of -$352000.0 in Q3 2021.
  • Its 5-year average for Other Non Operating Income is $113000.0, with a median of -$173000.0 in 2024.
  • As far as peak fluctuations go, Angiodynamics' Other Non Operating Income tumbled by 242000.0% in 2022, and later skyrocketed by 238151.26% in 2025.
  • Angiodynamics' Other Non Operating Income (Quarter) stood at -$10000.0 in 2021, then crashed by 2420.0% to -$252000.0 in 2022, then soared by 87.3% to -$32000.0 in 2023, then skyrocketed by 137.5% to $12000.0 in 2024, then plummeted by 1166.67% to -$128000.0 in 2025.
  • Its Other Non Operating Income stands at -$128000.0 for Q4 2025, versus -$178000.0 for Q3 2025 and -$325000.0 for Q2 2025.